About
Tests
News
Contact
Order Tests

National Cancer Center $397,000 Grant

by Jean Rodriguez | Feb 1, 2022 | Industry | 0 comments

The National Cancer Institute awards $397,000 grant to Precision Epigenomics

Search

Recent Posts

2024 Flinn Foundation Bioscience Entrepreneurship Program Partner
Annual Association For Molecular Pathology Presentation
Digestive Disease Week Presentation
Multi-Cancer Detection Assay on Pleural Fluid Publication
American Thoracic Society Presentation

Recent Comments

No comments to show.

The EPISEEK test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The EPISEEK test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK is intended to detect cancer signals. Use of EPISEEK is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK false positive) or confirmatory testing was insufficient to detect cancer (follow up testing false negative). False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Quick Links

Home
About
Tests
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way Ste 280B Tucson, AZ 85711



520.372.7522